22nd Century Group (NASDAQ:XXII) Issues Quarterly Earnings Results

22nd Century Group (NASDAQ:XXII – Get Free Report) posted its earnings results on Monday. The biotechnology company reported ($247.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($174.00) by ($73.80), FiscalAI reports. 22nd Century Group had a negative net margin of 27.04% and a negative return on equity of 69.37%. The business had revenue of $4.76 million during the quarter, compared to analyst estimates of $8.42 million.

22nd Century Group Stock Performance

Shares of NASDAQ:XXII opened at $0.77 on Monday. 22nd Century Group has a 12 month low of $0.72 and a 12 month high of $20,314.50. The company has a quick ratio of 1.90, a current ratio of 2.61 and a debt-to-equity ratio of 0.02. The company’s fifty day simple moving average is $49.18 and its 200 day simple moving average is $1,678.79. The firm has a market cap of $7,701.00, a price-to-earnings ratio of -0.00 and a beta of 0.76.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 22nd Century Group in a research report on Monday, October 26th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock has an average rating of “Sell”.

View Our Latest Analysis on XXII

22nd Century Group Company Profile

(Get Free Report)

22nd Century Group, Inc. was a biotechnology company focused on developing tobacco products with reduced nicotine content. Its research centered on genetically modified tobacco plants and cigarette formulations designed to lower nicotine exposure and support smoking cessation or harm-reduction efforts. The company’s principal product was VLN cigarettes, which were made with very low nicotine tobacco and marketed as containing substantially less nicotine than conventional cigarettes. 22nd Century also historically developed and commercialized other reduced-nicotine cigarette products, including Quest, and pursued applications of its plant-science technology in the tobacco and cannabinoid sectors.

Read More

Earnings History for 22nd Century Group (NASDAQ:XXII)

Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.